HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

"This is changing the way we practice prostate cancer." ...

Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy combination in prostate cancer. The collaboration focuses on evaluating J&J’s ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...